Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mizoribine - Asahi Kasei Pharma Corp

Drug Profile

Mizoribine - Asahi Kasei Pharma Corp

Alternative Names: Bredinin; HE-69

Latest Information Update: 29 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asahi Kasei
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Chong Kun Dang
  • Class Antirheumatics; Ribonucleosides; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lupus nephritis; Nephrotic syndrome; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 01 Nov 2018 Asahi Kasei completes a phase III trial for Nephrotic syndrome (Treatment-resistant) in China (NCT02257697)
  • 24 Jun 2018 Biomarkers information updated
  • 06 Feb 2017 Mizoribine is still in phase III trials for Nephrotic syndrome (Treatment-resistant) and Lupus nephritis in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top